The Business Model
Who profits from Dutch transgender care — and what is the sector expecting for 2026 and beyond?
The first Dutch gender team started in 1973 in the then VU hospital (source). In 2022 there were about 5,500 new registrations at providers of transgender care and, after correcting for duplicates, about 6,900 people waiting for assessment for somatic care (gross about 9,300), with an average wait of almost two years (source).
A treatment error with a business model. Follow the money.
Providers
Gender care in the Netherlands is provided by Amsterdam UMC, other academic centres and a growing number of private providers (below). This site has no verified revenue figures per provider, so none are given.
1. Amsterdam UMC (KZcG) — the cradle
The Centre of Expertise on Gender Dysphoria (KZcG) at Amsterdam UMC, VUmc site, has treated the vast majority of Dutch gender patients since the 1970s (source).
2018 annual report: ~€13M revenue, +3.3% growth, ~70 new adult patients/month, ~40 new child patients/month, 22,000 consultations/year, ~700 surgeries/year (source).
No revenue figures for 2024/2025 are available to this site.
See also: Current status in the Netherlands, Origins — VUmc Amsterdam.
2. UMCG and Radboud UMC
UMCG (Groningen) — second-largest integrated provider. Adults only until 2024; since 2024 also youth care, partly under pressure from the waiting lists elsewhere.
Radboud UMC (Nijmegen) — active in transgender care since 2020, treats both adults and children.
3. The growing private market
Besides the academic centres, private providers now offer gender care, as the cards below show.
Gender Clinic B.V.
Bosch en Duin, registered KvK 73309001. January 2026: alliance with Amsterdam UMC for low-complexity, high-volume gender surgery.
Medische Kliniek Velsen
Active since 2020, performing both MtF and FtM gender-affirming surgery.
Mutsaersstichting / OOG
Gender Team South — Venlo, Eindhoven, Helmond. Diagnostics and psychological support.
Genderhealthcare
Private provider of gender care.
4. The pharmaceutical revenue stream
Transgender care is a long-term medication market. With tens of thousands of Dutch people on hormone substitution, this is a structural, predictable pharma market.
| Drug | Population | Duration |
|---|---|---|
| Puberty blockers (triptorelin, leuprorelin) | Adolescents | 2–6 yrs |
| Estradiol | Trans women | Lifelong |
| Testosterone | Trans men | Lifelong |
| Anti-androgens | Trans women | Until surgery |
5. Who pays
- Health insurers — Zilveren Kruis, VGZ, CZ, Menzis
- Patients — own-risk excess from age 18; under 18 falls under the Youth Act
- National government — basic insurance and (partially) the Youth Act
The financing of transgender care was outside the scope of the SiRM study (2023) (source), and this site has no verified total for the costs.
6. The waiting list
In 2022 the average wait between registration and intake for assessment had risen to almost two years. After correcting for duplicates about 6,900 people were waiting for assessment for somatic care; SiRM estimated that 68-80% of those on the waiting lists were unique individuals, because many people register with several providers (source).
SiRM (citing the Kwartiermaker Transgenderzorg and Transvisie, 2019) writes that the long wait has a strongly negative influence on the mental wellbeing and societal position of those waiting.
7. Outlook 2026 and beyond
Further commercialisation
The Amsterdam UMC × Gender Clinic alliance (January 2026) is likely the first of several public-private partnerships.
The Cass effect
In March 2024 NHS England decided that puberty blockers are no longer available as a routine commissioning treatment option for under-18s (source), and the Cass Review followed in April 2024. According to the Cass Review, the Finnish and Swedish guidelines recommend medical treatment, given the lack of evidence, only within a research framework (source). The Netherlands kept its approach: on 30 June 2026 the Gezondheidsraad wrote that Dutch care is carefully organised and saw no reason to organise it differently (source); see also Response VUmc / Amsterdam UMC.
Insurance pressure
Coverage in 2026 still sits fully in the basic insurance package. With rising healthcare costs, a revision — particularly for elective components — is not unthinkable.
New growth segments
- Non-binary care — new revenue model
- Detransition care — untapped market, internationally rising
- Fertility preservation — premium segment for young people starting hormone therapy
Conclusion
Dutch transgender care has grown from an academic niche into a sector with several academic and private providers. In 2018 the Amsterdam UMC centre alone had a turnover of almost EUR 13 million (source).
The real question for 2026 is not whether the sector keeps growing, but where the money flows — and what The Hague does if the Cass doctrine breaks through here too.
Related on this site
Sources
- Amsterdam UMC, Gender Care in Development — Annual Report 2011-2018 (vumc.nl)
- Wikipedia, Transgender care in the Netherlands, July 2024
- Dutch Government, Research into demand for transgender care, SiRM 2023
- ZonMw / Radboud University, My Gender Whose Care?, May 2023
- Future vision Transgender Care, Zorgvuldig Advies / Kwartiermaker
- Amsterdam UMC press releases January 2025, January 2026, April 2024
- Genderhealthcare.com waiting-time updates 2022–2025
- Transgender Netwerk Nederland, July 2025
- Vasterman Blog, Transgender care statistics, 2022
- Zorgverzekeringwijzer.nl, Transgender care coverage 2026, November 2025
- Cass Review (UK, 2024) + Amsterdam UMC response
- TransFirm.nl / KvK 73309001 — Gender Clinic B.V.